UNITED STATES INTERNATIONAL TRADE COMMISSION
`
`Washington, D.C.
`
`In the Matter of
`
`CERTAIN PRE-FILLED SYRINGES FOR
`INTRA VITREAL INJECTION AND
`COMPONENTS THEREOF
`
`INV. NO. 337-TA-1207
`
`ORDER NO. 20: MODIFYING THE PROCEDURAL SCHEDULE
`
`(December 10, 2020)
`
`On December 9, 2020, complainants Nova1tis Phatma AG, Novattis Phatmaceuticals
`
`Corporation, and Novattis Technology LLC ( collectively, "Novattis") and respondent Regeneron
`
`Phatmaceuticals, Inc. ("Regeneron") filed a joint motion ("Mot.") seeking to modify ce1tain dates in
`
`the procedural schedule issued as Order No. 8 on August 17, 2020. Motion Docket No. 1207-017.
`
`The Commission Investigative Staff does not oppose the requested relief. See Mot. at 1.
`
`Unopposed Motion No. 1207-017 is granted. The remainder of this investigation shall be
`
`conducted in accordance with the following schedule:
`
`Event
`
`Fact discove1y cutoff and completion
`
`Deadline for final contentions on issues for which the
`patty bears the burden of proof
`
`Deadline for final contentions on issues for which the
`patty does not bear the burden of proof
`
`Date
`
`December 18, 2020
`
`December 23, 20201
`
`December 23, 2020
`
`Deadline for motions to compel discove1y
`
`December 29, 2020
`
`1 Dates that differ from those set fo1th in Order No. 8 are indicated by italic typeface.
`
`Novartis Exhibit 2048.001
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`Washington, D.C.
`
`In the Matter of
`
`CERTAIN PRE-FILLED SYRINGES FOR
`INTRA VITREAL INJECTION AND
`COMPONENTS THEREOF
`
`INV. NO. 337-TA-1207
`
`ORDER NO. 20: MODIFYING THE PROCEDURAL SCHEDULE
`
`(December 10, 2020)
`
`On December 9, 2020, complainants Nova1tis Phatma AG, Novattis Phatmaceuticals
`
`Corporation, and Novattis Technology LLC ( collectively, "Novattis") and respondent Regeneron
`
`Phatmaceuticals, Inc. ("Regeneron") filed a joint motion ("Mot.") seeking to modify ce1tain dates in
`
`the procedural schedule issued as Order No. 8 on August 17, 2020. Motion Docket No. 1207-017.
`
`The Commission Investigative Staff does not oppose the requested relief. See Mot. at 1.
`
`Unopposed Motion No. 1207-017 is granted. The remainder of this investigation shall be
`
`conducted in accordance with the following schedule:
`
`Event
`
`Fact discove1y cutoff and completion
`
`Deadline for final contentions on issues for which the
`patty bears the burden of proof
`
`Deadline for final contentions on issues for which the
`patty does not bear the burden of proof
`
`Date
`
`December 18, 2020
`
`December 23, 20201
`
`December 23, 2020
`
`Deadline for motions to compel discove1y
`
`December 29, 2020
`
`1 Dates that differ from those set fo1th in Order No. 8 are indicated by italic typeface.
`
`Novartis Exhibit 2048.001
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`Event
`
`Monthly case management conference
`
`Exchange initial expe1i reports (identify
`tests/ surveys/ data)
`
`Exchange rebuttal expert repo1is
`
`One-day mediation session
`
`Monthly case management conference
`
`Date
`
`January 14, 2021
`at 10:30 a.m.
`
`January 22, 2021
`
`February 5, 2021
`
`By Febma1y 10, 2021
`
`February 18, 2021
`at 10:30 a.m.
`
`Deadline for filing sunnnaiy dete1mination motions
`
`Febma1y 18, 2021
`
`Expert discove1y cutoff and completion
`
`Exchange of exhibit lists among the paiiies of proposed
`direct exhibits
`
`Complainant and respondent se1ve proposed direct
`exhibits, and identify physical exhibits2
`
`Submit joint repo1i on mediation
`
`Staff se1ves proposed direct exhibits, and identifies
`physical exhibits
`
`Se1ve proposed rebuttal exhibits, and identify rebuttal
`physical exhibits
`
`Complainants and respondent file pre-trial statements and
`briefs
`
`Monthly case management conference
`
`File joint list of unopposed exhibits
`
`Staff files pre-trial statement and brief
`
`Deadline for motions in limine
`
`February 22, 2021
`
`February 24, 2021
`
`March 2, 2021
`
`March 3, 2021
`
`Mai·ch 5, 2021
`
`Mai·ch 9, 2021
`
`Mai·ch 12, 2021
`
`March 18, 2021
`at 10:30 a.m.
`
`March 23, 2021
`
`March 26, 2021
`
`Mai·ch 31 , 2021
`
`2 The paiiies represent they will separately stipulate as to a schedule for exchanging direct and
`rebuttal demonstratives and objections in the event of live testimony at the evidentiaiy hearing.
`
`2
`
`Novartis Exhibit 2048.002
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`Event
`
`Deadline for responses to motions in limine
`
`Date
`
`April 8, 2021
`
`Final pre-hearing conference
`
`April 16, 2021 at 9:00 a.m.
`
`Hearing
`
`File final exhibit list
`
`Complainant and respondent file post-hearing initial briefs
`with the Secretaiy and submit final exhibits with the
`Administrative Law Judge
`
`Staff files post-hearing initial brief
`
`Complainant and respondent file post-hearing responsive
`briefs
`
`Staff files post-hearing responsive brief
`
`Final initial determination
`
`April 19-23, 2021 at 9:00 a.m.
`
`April 29, 2021
`
`May 14, 2021
`
`May 21 , 2021
`
`May 28, 2021
`
`June 4, 2021
`
`July 29, 2021
`
`Target date for completion of investigation
`
`November 29, 2021
`
`SO ORDERED.
`
`Clark S. Cheney
`Administrative Law Judge
`
`3
`
`Novartis Exhibit 2048.003
`Regeneron v. Novartis, IPR2020-01317
`
`
`
`CERTAIN PRE-FILLED SYRINGES
`FOR INTRAVITREAL INJECTION
`AND COMPONENTS THEREOF
`
`
`Inv. No. 337-TA-1207
`
`PUBLIC CERTIFICATE OF SERVICE
`
`I, Lisa R. Barton, hereby certify that the attached ORDER has been served via EDIS
`upon the Commission Investigative Attorney, W. Peter Guarnieri, Esq., and the following
`parties as indicated, on December 11, 2020.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`On Behalf of Complainants Novartis Pharma AG, Novartis
`Pharmaceuticals Corporation, and Novartis Technology LLC:
`
`Elizabeth J. Holland, Esq.
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018
`Email: EHolland@goodwinlaw.com
`
`On Behalf of Respondent Regeneron Pharmaceuticals, Inc.:
`
`Anish R. Desai, Esq.
`WEIL, GOTSHAL & MANGES LLP
`767 5th Avenue
`New York, NY 10153
`Email: anish.desai@weil.com
`
`
`
`
`
`
`
`Lisa R. Barton, Secretary
`U.S. International Trade Commission
`500 E Street, SW, Room 112
`Washington, DC 20436
`
`
`
`
`☐ Via Hand Delivery
`☐ Via Express Delivery
`☐ Via First Class Mail
`☒ Other: Email Notification
`of Availability for Download
`
`
`
`☐ Via Hand Delivery
`☐ Via Express Delivery
`☐ Via First Class Mail
`☒ Other: Email Notification
`of Availability for Download
`
`Novartis Exhibit 2048.004
`Regeneron v. Novartis, IPR2020-01317
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
